Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Heatmap
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
FBRX
#3021
Forte Biosciences, Inc. - Common Stock
0.1
9
USD
-99.12%
Sector:
Healthcare
Base:
USD
Profit Currency:
USD
Daily Range
Year Range
Daily Change
-99.12%
Monthly Change
-99.32%
6 month change
-99.35%
Year Change
-99.35%
Previous Close
21.7
2
Open
0.1
9
Low
0.1
9
High
0.1
9
Volume
28
Markets
US Stock Market
Healthcare
FBRX
Open full chart
Full chart
Financials
Overview
Statement
Statistics
Quarterly
Annual
Value
2020
2021
2022
2023
2024
2025
Current
Key stats
Total common shares outstanding
540.35 K
590.45 K
840.28 K
1.46 M
6.58 M
13.89 M
13.91 M
Valuation ratios
Enterprise value
433.09 M
-10.45 M
-18.83 M
-6.92 M
127.23 M
301.71 M
—
Price to earnings ratio
—
—
-1.32
-0.83
-1.87
-5.79
-4.72
Price to sales ratio
—
—
—
—
—
—
—
Price to cash flow ratio
—
—
-2.25
—
—
—
—
Price to book ratio
—
—
0.47
—
—
—
—
Enterprise value to EBITDA ratio
—
—
—
0.22
-3.59
-4.43
—
Profitability ratios
Return on assets %
-0.76
-0.5
-0.33
-0.81
-0.58
-0.84
-0.33
Return on equity %
-0.79
-0.52
-0.36
-0.89
-0.68
-1.14
-0.53
Return on invested capital %
-3 279.79
-8 081.24
-8 739.62
-22.82 K
-33.73 K
-13.1 K
-4 243.29
Gross margin %
—
—
—
100
100
100
—
Operating margin %
—
—
—
-2 890.21
-2 785.54
-2 602.47
—
EBITDA margin %
—
—
—
-2 789.41
-2 694.6
-2 508.84
—
Net margin %
—
—
—
-2 800.36
-2 700
-2 555.25
—
Liquidity ratios
Quick ratio
—
—
—
—
—
—
—
Current ratio
26.52
24.19
13.06
10.45
6.76
3.88
2.75
Inventory turnover
—
—
—
—
—
—
—
Asset turnover
—
—
—
0.03
0.03
0.03
—
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
—
—
-11.77
—
—
—
—
EBIT per share
—
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
—
Cash per share
—
—
59.11
—
—
—
—
Net current asset value per share
—
—
59.7
—
—
—
—
Tangible book value per share
—
—
55.83
—
—
—
—
Working capital per share
—
—
55.13
—
—
—
—
Book value per share
—
—
55.83
—
—
—
—
News
Forte Biosciences Stock: Targeting Celiac Disease (NASDAQ:FBRX)
AnaptysBio: 'Hold' As Spin-Off Shifts Pipeline To First Tracks Biotherapeutics (ANAB)
Forte Biosciences: 2026 Is Major Inflection Point For FB102 (NASDAQ:FBRX)
Forte Biosciences: Bull Run Could Continue Thanks To Near-Term Data Readouts
Forte Biosciences (FBRX) Upgraded to Buy: Here's What You Should Know
Micron, Insmed among market cap stock movers on Thursday
Evercore ISI initiates coverage on Forte Biosciences stock with Outperform rating
Guggenheim initiates Forte Biosciences stock with Buy rating on autoimmune therapy potential
Forte Biosciences Announces Pricing of $75 Million Public Offering
Forte Biosciences Stock (FBRX) Surges 25% on Positive Celiac Disease Trial Data - TipRanks.com
Morning News Wrap-Up: Monday’s Biggest Stock Market Stories! - TipRanks.com
Forte’s celiac disease drug shows positive results in Phase 1b trial